B+
Bull case
30%
Probability
Target price
$335.00
Analysis reference price unavailable
Analysis 2026-05-03 · RankAlpha Sentiment Codex
CI
Cigna GroupANYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
The core bullish read is that Q1 combined a clean beat/raise with better Cigna Healthcare profitability: adjusted EPS was $7.79, full-year outlook moved to at least $30.35, Cigna Healthcare pre-tax operating income rose 18%, and reported MCR improved to 79.8% in Q1. Available post-print sell-side reaction is constructive but still early, with Mizuho raising its target to $330 from $325 while keeping Outperform.
Posture
Constructive
Lead driver
Sentiment
What changed
2 setup hits (3d) with net bullish as of 2026-09-09.
What can break
Cigna remains exposed to drug-pricing changes, pharmacy-network shifts, government-program participation, and broader regulatory change, all of which are explicitly flagged in the 10-Q risk language. [#10-Q-2026-04-30]
Momentum
27
Value
70
Sentiment
76
Setup hits (3d)
2 · Net Bullish
AI TargetsBase $315.00 · Bull $335.00 · Bear $255.00Analysis 2026-05-03; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-03 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Bullish
Target $341.17
Why
Momentum27 · Δ7d +7.2
Value70 · Δ7d -0.0
Sentiment76 · Δ7d +10.3
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Confirming evidence
- • 2 setup hits (3d) with net bullish as of 2026-09-09.
- • Sentiment remains the lead driver in the composite, 7D delta +10.3.
Contradictions & invalidation
- • Cigna remains exposed to drug-pricing changes, pharmacy-network shifts, government-program participation, and broader regulatory change, all of which are explicitly flagged in the 10-Q risk language. [#10-Q-2026-04-30]
- • Pharmacy Benefit Services pre-tax operating income fell 28% year over year, primarily from lower contributions from large client relationships, showing that Evernorth mix is still uneven despite revenue growth. [#8-K-2026-04-30]
- • The bear read is that the quarter did not fully resolve the key skepticism around Evernorth’s PBM earnings power: Pharmacy Benefit Services pre-tax income fell 28% despite revenue growth, total pharmacy customers fell 2%, and some news coverage tied the mixed stock reaction to PBM profit pressure and the announced ACA marketplace exit.
Catalyst clock
2026-05-15
Post-Q1 beat-and-raise revision cycle
Lead driver: Sentiment · See AI snapshot
Momentum
27
9% active weight
Current posture
7d trendImproving
Δ7d
+7.2
Δ21d
+2.8
Value
70
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.2
Sentiment
76
62% active weight
Current posture
7d trendImproving
Δ7d
+10.3
Δ21d
+3.3
Why this grade
Composite grade A. Momentum 26.6 / Value 70.0 / Sentiment 75.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-03. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$315.00
Analysis reference price unavailable
Analysis 2026-05-03 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$255.00
Analysis reference price unavailable
Analysis 2026-05-03 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$72.75B
Beta
0.28
Shares Out
264.24M
P/E (TTM)
12.5
P/S (TTM)
0.28
P/FCF (TTM)
12.99
Rev YoY
+6.5%
EPS YoY
+10.1%
Gross Margin
+9.6%
Op Margin
+3.9%
Net Debt
$23.79B
Current Ratio
0.85
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data